Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis

被引:5
|
作者
Yang, Huili [1 ,2 ]
Feng, Lian [1 ,2 ]
Xu, Linyi [1 ,2 ]
Jiang, Dansheng [1 ,2 ]
Zhai, Fenfen [3 ]
Tong, Guangdong [1 ]
Xing, Yufeng [1 ]
机构
[1] Shenzhen Tradit Chinese Med Hosp, Hepatol Dept, Shenzhen 518033, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen 518033, Guangdong, Peoples R China
[3] Shenzhen Futian Ctr Chron Dis Control, Shenzhen 518048, Guangdong, Peoples R China
关键词
APOLIPOPROTEIN-B; PPAR-ALPHA; MICROBIOTA; METABOLISM; PROGRESSION; DEFICIENCY; DISORDERS; BACTERIA; RECEPTOR; OBESITY;
D O I
10.1155/2022/4801695
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing incidence rate but few therapies. Shugan Xiaozhi decoction (SX) has demonstrated beneficial effects in treating NAFLD with an unclear mechanism. This study was aimed at investigating the therapeutic mechanism of SX on high-fat diet-induced NAFLD rats via the gut-liver axis. Hepatic steatosis and integrity of intestinal mucosa in NAFLD rats were assessed by histopathological staining. The level of lipid and inflammation were estimated by enzyme-linked immunosorbent assay. Western Blotting was used to detect apolipoprotein (apo) B48 expression. 16S rRNA analysis was used to measure the changes of gut microbial composition after SX treatment. The expressions of zona occludens 1 protein (ZO-1), occludin, and secretory immunoglobulin A (sIgA) in the colon were detected by immunostaining to investigate the intestinal barrier function. Our study found that SX reduced hepatic steatosis, the levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, and triglyceride and apoB48 expression but increased peroxisome proliferator activated receptor alpha (PPAR alpha) level. Moreover, SX altered the diversity of gut microbiota, upregulating the relative abundance of f_Prevotellaceae, while downregulating f_Bacteroidales_ S24-7, f_Lachnospiraceae, f_Ruminococcaceae, f_Erysipelotrichaceae, and f_Desulfovibrionaceae. By increasing the expression of ZO-1 and occludin and decreasing the level of proinflammatory factors, including sIgA, lipopolysaccharide, tumor necrosis factor-alpha, interleukin-1 beta, monocyte chemotactic protein-1, and transforming growth factor-beta 1, SX improved intestinal mucosal integrity and barrier function. Our study illustrated that the gut-liver axis was a potential way for SX to ameliorate NAFLD, that is, by regulating the expression of PPAR alpha, apoB48, and modulating gut microbiota to protect the intestinal barrier function, and thus alleviate lipid deposition and inflammatory response in the liver.
引用
下载
收藏
页数:15
相关论文
共 50 条
  • [31] The gut-liver axis and gut microbiota in health and liver disease
    Hsu, Cynthia L.
    Schnabl, Bernd
    NATURE REVIEWS MICROBIOLOGY, 2023, 21 (11) : 719 - 733
  • [32] The gut-liver axis as a target of liver disease management
    Mandato, Claudia
    Bovi, Anna Pia Delli
    Vajro, Pietro
    HEPATOBILIARY SURGERY AND NUTRITION, 2021, 10 (01) : 100 - 102
  • [33] Viral Liver Disease and Intestinal Gut-Liver Axis
    Kouroumalis, Elias
    Tsomidis, Ioannis
    Voumvouraki, Argyro
    GASTROINTESTINAL DISORDERS, 2024, 6 (01): : 64 - 93
  • [34] The Gut-Liver Axis in Pediatric Liver Health and Disease
    Rager, Stephanie L.
    Zeng, Melody Y.
    MICROORGANISMS, 2023, 11 (03)
  • [35] Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease
    Paolella, Giulia
    Mandato, Claudia
    Pierri, Luca
    Poeta, Marco
    Di Stasi, Martina
    Vajro, Pietro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15518 - 15531
  • [36] Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
    Scarpellini, E.
    Lupo, M.
    Iegri, C.
    Gasbarrini, A.
    De Santis, A.
    Tack, J.
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (03) : 141 - 147
  • [37] Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis
    Zhu, Weifeng
    Zhou, Ying
    Tsao, Rong
    Dong, Huanhuan
    Zhang, Hua
    FRONTIERS IN NUTRITION, 2022, 9
  • [38] Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease
    Giulia Paolella
    Claudia Mandato
    Luca Pierri
    Marco Poeta
    Martina Di Stasi
    Pietro Vajro
    World Journal of Gastroenterology, 2014, 20 (42) : 15518 - 15531
  • [39] The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Martin-Mateos, Rosa
    Albillos, Agustin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [40] The gut-liver axis
    Visschers, Ruben G. J.
    Luyer, Misha D.
    Schaap, Frank G.
    Damink, Steven W. M. Olde
    Soeters, Peter B.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2013, 16 (05): : 576 - 581